DANBURY, Conn., March 20 Biodel Inc.(Nasdaq: BIOD) today announced that Gerard Michel, Chief Financial Officer,Vice President of Corporate Development and Treasurer of Biodel, will presenta corporate update at the BioCentury Future Leaders Conference on Thursday,March 27, 2008 at 3:00 p.m. Eastern Time. The conference will be held at theMillennium Broadway Hotel and Conference Center in New York City.
Interested parties may access a link to a live webcast of the corporatepresentation in the investor relations section of Biodel's website atwww.biodel.com. An archive of the presentation will be available at the samelocation.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on thedevelopment and commercialization of innovative treatments for endocrinedisorders, such as diabetes and osteoporosis. Biodel's product candidates aredeveloped by using VIAdel(TM) technology, which reformulates existing FDA-approved peptide drugs. The Company's lead product candidate, VIAject(TM), isan ultra rapid-acting injectable meal-time insulin in development for use bypatients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being testedin two pivotal Phase III clinical trials. Biodel's pipeline also includesVIAtab(TM), a sublingual tablet formulation of insulin in the Phase I stage ofclinical testing, and two pre-clinical osteoporosis product candidates. Forfurther information regarding Biodel, please visit the Company's website atwww.biodel.com.BIOD-G
SOURCE Biodel Inc.